期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 12, 期 9, 页码 2219-2231出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2016.1175694
关键词
immunotherapy; immune checkpoint inhibitors; melanoma; nivolumab; non-small cell lung cancer; renal cell carcinoma
资金
- Intramural Research Program, Center for Cancer Research, National Cancer Institute/National Institutes of Health
- NATIONAL CANCER INSTITUTE [ZIABC011547, ZIABC010945] Funding Source: NIH RePORTER
The development of immune checkpoint inhibitors has altered the landscape of treatment of advanced cancers. These drugs are well tolerated and have shown clinical activity against a wide variety of solid tumors and hematological malignancies. The durability of response is particularly impressive when compared to other forms of systemic therapy. Nivolumab (Opdivo) is an IgG4 antibody that causes immune checkpoint blockade by diminishing inhibitory signaling through the programmed death receptor-1 pathway. It is approved for treatment of recurrent non-small cell lung cancer, melanoma, and renal cell carcinoma. Efforts to identify biomarkers of response to nivolumab are ongoing. Clinical trials are also being conducted to determine the benefits of combining nivolumab with other forms of treatment including chemotherapy, molecular-targeted therapy, radiation therapy, and other forms of immune therapy. This review outlines the clinical trials that have led to the emergence of nivolumab as a treatment option for patients with advanced cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据